YOLFTbeta
Atossa Genetics Inc

Atossa Genetics Inc

ATOS · NASDAQ · Healthcare / Biotechnology

1.96USD+0.02 (+1.03%)

Price History

Full chart

Market Stats

Previous Close1.94
Open1.91
Day Range1.85 – 2.00
52-Week Range1.70 – 19.35
Volume56.35K
Market Cap18.96M
P/E (TTM)0.00
Forward P/E7.04
EPS-4.34
Dividend Yield0.00%
Beta1.27
50-Day Avg2.43
200-Day Avg4.99

About

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Steven C. Quay FCAP, M.D., Ph.D.
  • Employees16
  • Headquarters448 NW Market Street, Seattle, WA, United States, 98107, USA
  • Websitehttps://www.atossatherapeutics.com

Leadership

  • Dr. Steven C. Quay FCAP, M.D., Ph.D.Chairman, CEO & President · b. 1951
  • Mr. Mark J. Daniel CPAChief Financial Officer · b. 1977
  • Ms. Janet Rose Rea MSPH, RACSenior Vice President of Research & Development
  • Ms. Delly Behen P.H.R.Senior Vice President of Business Operations
  • Dr. Richard Graydon M.D., Ph.D.Interim Chief Medical Officer

Financials

Income Statement

Currency: USD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--1.50K481.84K632.56K40.14K1.76K0000000000
Growth (%)---+32022.80%+31.28%-93.65%-95.62%-100.00%---------
Cost of Revenue--97.19K65.63K495.46K340.66K132.41K303.48K128.99K44.20K52.79K46.60K23.00K8.00K23.00K17.00K16.00K
Gross Profit---95.69K416.21K137.09K40.14K-130.65K-303.48K-128.99K-44.20K-52.79K-46.60K-23.00K-8.00K-23.00K-17.00K-16.00K
Gross Margin---6379.33%86.38%21.67%100.00%-7431.91%----------
Operating Expense--3.33M5.49M10.92M12.21M12.63M6.95M7.06M11.39M17.21M14.56M20.50M27.68M31.35M27.60M37.13M
Operating Income-122.86K-1.08M-3.43M-5.07M-10.78M-12.17M-12.76M-7.25M-7.19M-11.43M-17.27M-14.61M-20.52M-27.69M-31.38M-27.62M-37.14M
Operating Margin---228612.67%-1052.01%-1704.93%-30322.96%-725746.19%----------
EBITDA-122.86K-1.09M-3.41M-4.94M-10.31M-9.35M-12.49M-6.07M-7.80M-11.39M-17.21M-14.56M-20.58M-27.68M-30.07M-25.49M-34.75M
EBITDA Margin---227243.53%-1024.66%-1630.11%-23292.83%-710238.40%----------
Net Income-122.86K-1.09M-3.44M-5.08M-10.78M-14.66M-15.76M-6.37M-8.12M-11.40M-17.24M-17.83M-20.61M-26.23M-30.09M-25.50M-34.77M
Net Income Margin---229484.60%-1054.26%-1704.94%-36518.83%-896491.64%----------
R&D21.25K120.00K-1.97K1.11M2.58M2.36M770.43K2.33M4.21M7.13M6.61M9.21M15.08M17.33M14.12M21.18M
R&D as % of Total Revenue---0.41%174.70%6421.51%134220.31%----------
Interest Expense-9.14K17.99K12.04K36015.77K00192.82K00938.79K85.00K8.00K---
Interest Expense % of Total Revenue--1199.47%2.50%0.06%39.29%0.00%----------

Balance Sheet

Currency: USD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets85.46K15.01K3.07M6.83M12.01M11.76M6.24M4.14M8.16M11.72M14.50M42.84M141.26M123.53M96.25M76.44M47.61M
Total Liabilities53.78K866.86K1.51M1.65M1.41M2.27M2.50M1.05M1.23M2.92M1.34M15.68M3.13M5.57M5.24M4.97M8.26M
Total Equity31.68K-851.85K1.56M5.18M10.60M9.50M3.74M3.10M6.94M8.81M13.16M27.17M138.14M117.96M91.02M71.48M39.35M
Cash84.36K10.25K1.91M1.73M6.34M8.50M3.72M3.03M7.22M10.38M12.69M39.66M136.38M110.89M88.46M71.08M41.30M
Total Debt5.00K189.00K1.01M-15.50K125.24K----50.48K18.05K-----
Net Debt-79.36K178.75K-905.74K-1.73M-6.32M-8.38M-3.72M-3.03M-7.22M-10.38M-12.64M-39.65M-136.38M-110.89M-88.46M-71.08M-41.30M

Cash Flow

Currency: USD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-75.18K-358.11K-3.49M-3.90M-8.83M-10.56M-13.95M-5.37M-6.59M-8.96M-9.13M-11.57M-16.47M-20.76M-20.94M-21.03M-29.76M
Investing Cash Flow---136.93K-134.58K-489.81K-343.26K-288.42K-9.21K-110.91K-110.91K-7.63K-9.37K-9.00K-4.73M-14.00K-19.00K-23.00K
Financing Cash Flow159.54K284.00K5.53M3.85M13.94M13.06M9.46M4.70M10.78M12.29M11.34M38.55M113.30M1.00K-1.48M3.67M0
Capital Expenditure40136.93K134.58K489.81K343.26K130.74K9.21K110.91K110.91K7.63K9.37K9.00K27.00K14.00K19.00K23.00K
Free Cash Flow-75.18K-358.11K-3.63M-4.03M-9.32M-10.90M-14.08M-5.38M-6.59M-9.07M-9.14M-11.58M-16.48M-20.79M-20.95M-21.05M-29.79M
Dividends Paid---000000--4.50M-----
FCF to OCF100.01%100.00%103.92%103.45%105.55%103.25%100.94%100.17%100.00%101.24%100.08%100.08%100.05%100.13%100.07%100.09%100.08%
Dividend Paid to FCF---0.00%0.00%0.00%0.00%0.00%0.00%---38.89%-----

Earnings

Report DateDec 20, 2012Mar 28, 2013May 15, 2013Aug 14, 2013Nov 12, 2013Mar 27, 2014May 14, 2014Aug 12, 2014Nov 12, 2014May 13, 2015Aug 6, 2015Nov 12, 2015Mar 30, 2016May 5, 2016Aug 12, 2016Nov 14, 2016Mar 16, 2017May 11, 2017Aug 14, 2017Nov 13, 2017Mar 8, 2018May 14, 2018Aug 13, 2018Nov 13, 2018Mar 28, 2019May 13, 2019Aug 13, 2019Nov 13, 2019Mar 26, 2020May 13, 2020Aug 13, 2020Nov 13, 2020Mar 31, 2021May 14, 2021Aug 13, 2021Nov 15, 2021Feb 28, 2022May 9, 2022Aug 8, 2022Nov 7, 2022Mar 22, 2023May 15, 2023Aug 14, 2023Nov 13, 2023Mar 28, 2024May 13, 2024Aug 12, 2024Nov 12, 2024Mar 31, 2025May 13, 2025Aug 12, 2025Nov 12, 2025Mar 26, 2026May 8, 2026Aug 7, 2026Nov 11, 2026
EPS Estimate--19.80-270.00-378.00-396.00-34.20-297.00---297.00-324.00-297.00-405.00--189.00-230.40-163.80--79.20-52.20-12.60-0.86-8.32-8.47-9.37--7.20-7.80-4.95-0.39-4.20-5.17-0.27-0.75-0.52-0.82-0.04-0.90-0.90-0.82-0.97-0.06-0.90-1.00-0.06-1.00-0.90-0.90-0.06-0.82-0.85-1.00-1.14-1.22-1.04-0.92
EPS Actual-274.24-19.80-378.00-459.00-594.00-27.00-270.00-23.49-23.81-351.00-297.00-405.00-162.00-13.30-135.0012.60-194.40-5.40-107.50-29.8334.20-0.71-43.50-9.60-18.75-0.62-12.00-5.40-3.90-0.32-6.45-5.10-0.88-0.60-0.90-0.60-0.04-0.60-0.75-0.90-0.90-0.05-1.20-0.75-0.09-0.75-0.75-0.90-0.05-0.75-1.05-1.05-1.34-1.11-0.95-
Surprise-0.00%-40.00%-21.43%-50.00%21.05%9.09%---18.18%8.33%-36.36%60.00%-28.57%105.47%-18.68%--35.73%42.85%371.43%17.44%-422.84%-13.34%-100.11%--66.67%30.77%21.21%17.95%-53.57%1.35%-225.93%20.00%-73.08%26.83%0.00%33.33%16.67%-9.76%7.22%16.67%-33.33%25.00%-50.00%25.00%16.67%0.00%21.01%8.54%-23.53%-5.00%-17.20%9.02%8.65%-
Timing--Pre-marketAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-market--

Key Statistics & Ratios

Market Cap18.96M
Enterprise Value-4.24M
Trailing P/E0.00
Forward P/E7.04
PEG Ratio0.00
Price / Sales1872.06
Price / Book0.81
EPS-4.34
Book Value2.69
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-39.23M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-89.23%
Return on Assets-50.69%
Shares Outstanding9.98M
Shares Float9.94M
Beta1.27
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 3 analystsTarget 18.67
  • Strong Buy
    2
  • Buy
    1

Ownership Breakdown

Institutions
17.39%
Insiders
1.85%
Retail / Other
80.76%

Top Institutional Holders

  • Vanguard Capital Management, LLC
    349.10K3.50%
  • Ameriprise Financial Inc
    255.13K2.56%
  • BlackRock Inc
    133.17K1.33%
  • Renaissance Technologies Corp
    109.01K1.09%
  • Geode Capital Management, LLC
    97.06K0.97%
  • UBS Group AG
    92.03K0.92%
  • Vanguard Fiduciary Trust Co
    52.23K0.52%
  • Millennium Management LLC
    46.51K0.47%
  • State Street Corp
    39.76K0.40%
  • Northern Trust Corp
    19.22K0.19%
  • Morgan Stanley - Brokerage Accounts
    16.20K0.16%
  • Vanguard Global Advisers, LLC
    3.09K0.03%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    256.14K2.57%
  • Columbia Small Cap Value Discv A
    201.43K2.02%
  • Fidelity Extended Market Index
    44.97K0.45%
  • Abante Quant Value FI
    40.20K0.40%
  • Columbia VP Small Cap Value Discovery 1
    35.78K0.36%
  • Fidelity Total Market Index
    14.38K0.14%
  • Fidelity Series Total Market Index
    12.64K0.13%
  • Vanguard Balanced Index Inv
    6.54K0.07%

Stock Splits

  • Feb 2, 20261:15
  • Apr 20, 20181:12
  • Aug 26, 20161:15